SCHEMBL4737427

SCHEMBL4737427

CNC1Cc2ccccc2C2CCCC(C(C)C)N2C1=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
XIAP P98170 4/20 0.48
BIRC3 Q13489 4/20 0.48
BIRC2 Q13490 4/20 0.48
ACE P12821 3/20 0.47
MME P08473 2/20 0.47
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
HTR2B P41595 1/20 0.39
KCNH2 Q12809 1/20 0.39
PDPK1 O15530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12747426 0.85 ACE (0.50) XIAPBIRC3BIRC2ACEMME
SCHEMBL24512848 0.78 XIAP (0.65) XIAPBIRC3BIRC2ACEMME
SCHEMBL24513267 0.78 XIAP (0.65) XIAPBIRC3BIRC2ACEMME
SCHEMBL10060259 0.77 XIAP (0.39) XIAPBIRC3BIRC2ACEMME
SCHEMBL10332043 0.75 ACE (0.53) XIAPBIRC3BIRC2ACEMME
SCHEMBL16838549 0.75 ACE (0.53) XIAPBIRC3BIRC2ACEMME
SCHEMBL12747479 0.74 ACE (0.40) XIAPBIRC3BIRC2ACEMME
SCHEMBL14170126 0.73 ADRA2A (0.42) XIAPBIRC3BIRC2ACEMME
SCHEMBL14169932 0.73 ADRA2A (0.43) XIAPBIRC3BIRC2ACEMME
SCHEMBL10079282 0.72 XIAP (0.36) XIAPBIRC3BIRC2ACEMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168798-B2 Caspase inhibitor prodrugs VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-01 US disclosed
US-20110137037-A1 CASPASE INHIBITOR PRODRUGS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 US disclosed
US-7879891-B2 such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-01 US disclosed
US-20070155718-A1 Caspase inhibitor prodrugs VERTEX PHARMACEUTICALS INCORPORATED 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155718-A1 Caspase inhibitor prodrugs CASP1, CASP5, CASP2 XIAP 61/4885BIRC3 24/4885BIRC2 51/4885
US-20110137037-A1 CASPASE INHIBITOR PRODRUGS CASP1, CASP5, CASP2 XIAP 61/4885BIRC3 24/4885BIRC2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.